- Home
- AUPH vs AAMI Comparison
AUPH vs AAMI Comparison
Compare AUPH & AAMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUPH
- AAMI
- Stock Information
- Founded
- AUPH 1993
- AAMI 1980
- Country
- AUPH Canada
- AAMI United States
- Employees
- AUPH N/A
- AAMI N/A
- Industry
- AUPH Biotechnology: Pharmaceutical Preparations
- AAMI Investment Managers
- Sector
- AUPH Health Care
- AAMI Finance
- Exchange
- AUPH Nasdaq
- AAMI Nasdaq
- Market Cap
- AUPH 1.4B
- AAMI 1.6B
- IPO Year
- AUPH 1999
- AAMI N/A
- Fundamental
- Price
- AUPH $11.47
- AAMI $44.17
- Analyst Decision
- AUPH Strong Buy
- AAMI Hold
- Analyst Count
- AUPH 2
- AAMI 3
- Target Price
- AUPH $13.00
- AAMI $39.67
- AVG Volume (30 Days)
- AUPH 1.9M
- AAMI 285.6K
- Earning Date
- AUPH 11-06-2025
- AAMI 10-30-2025
- Dividend Yield
- AUPH N/A
- AAMI 0.09%
- EPS Growth
- AUPH N/A
- AAMI 43.58
- EPS
- AUPH 0.42
- AAMI 2.41
- Revenue
- AUPH $260,111,000.00
- AAMI $538,200,000.00
- Revenue This Year
- AUPH $17.33
- AAMI $21.37
- Revenue Next Year
- AUPH $14.31
- AAMI $16.37
- P/E Ratio
- AUPH $27.48
- AAMI $18.36
- Revenue Growth
- AUPH 25.59
- AAMI 18.76
- 52 Week Low
- AUPH $6.55
- AAMI $22.60
- 52 Week High
- AUPH $13.54
- AAMI $51.65
- Technical
- Relative Strength Index (RSI)
- AUPH 47.42
- AAMI N/A
- Support Level
- AUPH $11.08
- AAMI N/A
- Resistance Level
- AUPH $11.87
- AAMI N/A
- Average True Range (ATR)
- AUPH 0.62
- AAMI 0.00
- MACD
- AUPH -0.14
- AAMI 0.00
- Stochastic Oscillator
- AUPH 44.06
- AAMI 0.00
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About AAMI Acadian Asset Management Inc. Common Stock
Acadian Asset Management Inc is a holding company that operates a systematic investment management business through its subsidiary, that offers institutional investors across the globe access to a diversified array of systematic investment strategies designed to meet a range of risk and return objectives.